| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $10.6M | +31.0% |
| R&D Expense | $68.4M | +24.5% |
| SG&A Expense | $41.0M | +57.0% |
| Operating Income | -$98.8M | -35.4% |
| Net Income | -$69.0M | -18.4% |
| EPS (Basic) | -$1.28 | +3.0% |
| EPS (Diluted) | -$1.28 | +3.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $430.6M | +2142.2% |
| Short-term Investments | $594.6M | +83.0% |
| Current Assets | $1.03B | +196.0% |
| Total Assets | $1.06B | +179.0% |
| Current Liabilities | $17.5M | +34.0% |
| Total Liabilities | $38.7M | +7.4% |
| Stockholders' Equity | $1.02B | +197.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$43.8M | +13.4% |
| Capital Expenditures | $359K | -80.6% |
| Investing Cash Flow | -$258.0M | -526.4% |
| Financing Cash Flow | $713.2M | +1097.7% |
| Free Cash Flow | -$44.2M | +15.7% |